Your session is about to expire
← Back to Search
Other
MBL949 Arm 4 for Obesity
Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 169
Summary
This trial is testing a new treatment called MBL949 to help people who are overweight or have Type 2 Diabetes. The study includes a period to check participants' health, followed by several weeks of treatment and a follow-up. MBL949 aims to help manage weight and blood sugar levels better than current treatments.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to day 169
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 169
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change-from-baseline in Weight
Frequency and Severity of Adverse Events
Trial Design
6Treatment groups
Active Control
Placebo Group
Group I: MBL949 Arm 4Active Control1 Intervention
MBL949 one 1.5 mg dose followed by seven doses of 2.2 mg
Group II: MBL949 Arm 1Active Control1 Intervention
MBL949 one 3 mg dose followed by two doses of 6 mg followed by five doses of 4.5 mg
Group III: MBL949 Arm 5Active Control1 Intervention
MBL949 one 3 mg dose followed by two doses of 6 mg followed by five doses of 7.5 mg
Group IV: MBL949 Arm 2Active Control1 Intervention
MBL949 two 3 mg doses followed by six doses of 4.5 mg
Group V: MBL949 Arm 3Active Control1 Intervention
MBL949 one 12 mg dose followed by seven doses of 4.5 mg
Group VI: PlaceboPlacebo Group1 Intervention
Placebo to MBL949
Find a Location
Who is running the clinical trial?
Novartis PharmaceuticalsLead Sponsor
2,911 Previous Clinical Trials
4,250,551 Total Patients Enrolled
6 Trials studying Obesity
793 Patients Enrolled for Obesity
Share this study with friends
Copy Link
Messenger